<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80660">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961947</url>
  </required_header>
  <id_info>
    <org_study_id>7374-CL-0102</org_study_id>
    <nct_id>NCT01961947</nct_id>
  </id_info>
  <brief_title>Study of ASP7374, Cell-culture-derived Influenza Vaccine</brief_title>
  <official_title>Phase 3 Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults ≥20 and &lt;65 Years of Age－</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMN Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture
      derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine
      (TIV) in adults ≥20 and &lt;65 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>seroconversion rate of hemagglutination inhibition (HI) antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>geometric mean titer (GMT) of HI antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seroprotection rate of HI antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT ratio of HI antibody titer (Day 29/Day 1)</measure>
    <time_frame>Day1 and Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroconversion rate of neutralizing antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroprotection of neutralizing antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of neutralizing antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT ratio of neutralizing antibody titer (Day 29/Day 1)</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactions associated with the vaccination</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Influenza</condition>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>ASP7374 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP7374</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>ASP7374 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>approved egg-derived TIV</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>TIV group</arm_group_label>
    <other_name>Influenza HA vaccine &quot;SEIKEN&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy or medically stable, as judged on the basis of history and concurrent
             diseases.

          -  Subject understands procedure of the protocol and is willing to comply with the
             protocol.

          -  Written informed consent has been obtained.

        Exclusion Criteria:

          -  Scheduled to receive another vaccine during the study.

          -  Received influenza HA vaccine within 180 days prior to screening.

          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination
             with the study vaccine, and received or scheduled to receive an inactivated vaccine
             or a toxoid within 7 days prior to vaccination with the study vaccine.

          -  Diagnosis of immune deficit in the past, has a family member (within the third degree
             of kinship) with a diagnosis of congenital immunodeficiency syndrome.

          -  Received one of the following medications or treatment prior to vaccination with the
             study vaccine.

          -  Received one of the following medications or treatment prior to vaccination with the
             study vaccine: Interferon formulation, Drugs which affect the immune system,
             corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood
             transfusion

          -  History of anaphylactic shock or an allergic reaction such as generalized eruption
             due to food (including chicken, poultry, foodstuffs derived from chicken, et al.) or
             drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the previous
             vaccination (influenza vaccine and others)

          -  History of seizures, except for febrile seizures in childhood
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP7374</keyword>
  <keyword>Approved egg-derived vaccine</keyword>
  <keyword>Prevention of seasonal influenza</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
